Inhibikase Therapeutics(IKT) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity August 14, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments. "During our second quarter of 2025, w ...